{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:52Z","timestamp":1787008612165,"version":"build-2736575974"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K16095"],"award-info":[{"award-number":["JP20K16095"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax is an oral B-cell lymphoma-2 protein inhibitor. It is a key drug for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia. However, venetoclax is administered at a fixed dose, irrespective of body surface area or weight. Furthermore, the plasma concentration of venetoclax varies widely between individuals and is influenced by diet. Therefore, individualized dosing using therapeutic drug monitoring (TDM) may help to optimize treatment in clinical practice. In this study, we aimed to develop a simple method to determine venetoclax concentrations in plasma. The analysis required the extraction of a 50-\u03bcL plasma sample and precipitation of proteins using acetonitrile extraction. Venetoclax and the internal standard (12.5-\u03bcg\/mL ibrutinib) were separated by high-performance liquid chromatography (HPLC). The calibration curve was linear over the plasma venetoclax concentration range 0.25\u201310\u00a0\u03bcg\/mL with a coefficient of determination (r2) of 0.9999. The coefficients of intra-day and inter-day validation were 0.8\u20134.1% and 1.3\u20133.3%, respectively. The assay accuracy was \u22122.8 to 1.6%, and the recovery was &amp;gt;97.2%. These results demonstrate a very simple, novel and sensitive HPLC-UV-based method for determining the concentration of plasma venetoclax, and confirm its applicability to the TDM of venetoclax in a clinical setting.<\/jats:p>","DOI":"10.1093\/chromsci\/bmac027","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:12:19Z","timestamp":1649211139000},"page":"480-483","source":"Crossref","is-referenced-by-count":17,"title":["Determination of Venetoclax Concentration in Plasma Using High-Performance Liquid Chromatography"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-0091","authenticated-orcid":false,"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[{"name":"Department of Medicinal Therapy Research , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"},{"name":"Meiji Pharmaceutical University , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"},{"name":"Meiji Pharmaceutical University , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"},{"name":"Meiji Pharmaceutical University , Pharmaceutical Education and Research Center, , 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Hematology , , 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"},{"name":"Tokyo Metropolitan Bokutoh Hospital , , 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-9320","authenticated-orcid":false,"given":"Masayuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology , , 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"},{"name":"Tokyo Metropolitan Bokutoh Hospital , , 4-23-15, Kotobashi, Sumida-ku, Tokyo 130-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"4","key":"2023060110392034600_ref1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"2023060110392034600_ref2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"2023060110392034600_ref3","author":"VENCLEXTA\u00ae Highlights of Prescribing Information"},{"issue":"11","key":"2023060110392034600_ref4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"The Journal of Clinical Pharmacology"},{"key":"2023060110392034600_ref5","doi-asserted-by":"crossref","first-page":"122176","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","author":"Eisenmann","year":"2020","journal-title":"Journal of Chromatography B"},{"key":"2023060110392034600_ref6","volume-title":"Guidance for industry: Bioanalytical method validation","author":"US DHHS, FDA, CDER, CVM","year":"2018"},{"issue":"3","key":"2023060110392034600_ref7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","article-title":"Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"113","author":"Izutsu","year":"2021","journal-title":"International Journal of Hematology"},{"issue":"6","key":"2023060110392034600_ref8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jjco\/hyab018","article-title":"Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings","volume":"51","author":"Taniguchi","year":"2021","journal-title":"Japanese Journal of Clinical Oncology"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/5\/480\/50487130\/bmac027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/5\/480\/50487130\/bmac027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T06:39:35Z","timestamp":1685601575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/61\/5\/480\/6563943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":8,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,5]]},"published-print":{"date-parts":[[2023,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmac027","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2022,4,5]]}}}